ClinicalTrials.gg
Active, not recruitingNCT04770779ENERGIZE-TUpdated Oct 28, 2026Results posted

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)

A Phase 3 interventional study of Placebo Matching Mitapivat and Mitapivat in Transfusion-dependent Alpha-Thalassemia and Transfusion-dependent Beta-Thalassemia, sponsored by Agios Pharmaceuticals, Inc.. Active, not recruiting at 75 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Primary conditionbeta-ThalassemiaRegistry: ThalassemiaReclassifiedWhy we changed it
Registry
Thalassemia — the first condition term the registry derived for this study.
ClinicalTrials.gg
beta-Thalassemia
Why
  1. The study's listed conditions name beta-Thalassemia, a narrower term within Thalassemia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Agios Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
258
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 91 studies in beta-Thalassemia with a site in United States — 22 open to participants now, 36 under way, 8 of them phase 3. beta-Thalassemia · United States.

Enrollment
5th of 71
258 · median 25
Started
2021
with 6 others
Phase 3
12 of 91
5 open now
Primary completion
2024-04
later than 2 of 35 live
Registered
66th of 91
by date
Lead sponsor
4 of 91
Agios Pharmaceuticals, Inc.

Among the 91 studies in beta-Thalassemia with a site in United States, this one is the 5th largest by enrollment of the 71 interventional ones that give a count, is one of 7 that started in 2021, is one of 12 in phase 3, reaches primary completion later than 2 of the 35 other live ones, and was the 66th registered.

beta-Thalassemia

294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.

Browse beta-Thalassemia studies →

Open to participants now

22 of the 91 studies in beta-Thalassemia with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in beta-Thalassemia with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study was to compare the effect of mitapivat versus placebo on transfusion burden in participants with α- or β-transfusion-dependent thalassemia.

Read the detailed description

The mitapivat group included 171 participants. The placebo group included 87 participants.

03

Conditions studied

  • Transfusion-dependent Alpha-Thalassemia
  • Transfusion-dependent Beta-Thalassemia

Browse trials for

04

In context

beta-Thalassemia Reclassified

294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.

This study's enrollment of 258 is above the median of 40 across 208 interventional studies indexed under beta-Thalassemia.

Browse beta-Thalassemia studies →

Lead sponsor

Agios Pharmaceuticals, Inc. is the lead sponsor of 52 studies on the registry; 6 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 4 (17%) have results posted.

Compared within beta-Thalassemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Thalassemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Greater than or equal to (≥)18 years of age at the time of providing ;
  • Documented diagnosis of thalassemia (β-thalassemia with or without α-globin gene mutations, E (HbE)/β-thalassemia, or α-thalassemia/hemoglobin H (HbH) disease) based on deoxyribonucleic acid (DNA) analysis;
  • Considered transfusion-dependent, defined as 6 to 20 red blood cells (RBC) units transfused and ≤6-week transfusion-free period during the 24-week period before randomization;
  • If taking hydroxyurea, the hydroxyurea dose must be stable for ≥16 weeks before randomization;
  • Women of (WOCBP) must be abstinent of sexual activities that may induce pregnancy as part of their usual lifestyle or agree to use two forms of , one of which must be considered highly effective, from the time of providing informed consent, throughout the study, and for 28 days after the last dose of study drug. The second form of contraception can be an acceptable barrier method;
  • Written informed consent before any study-related procedures are conducted and willing to comply with all study procedures for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Pregnant, breastfeeding, or parturient;
  • Documented history of homozygous or heterozygous sickle (Hb S) or hemoglobin C (Hb C);
  • Prior exposure to gene therapy or prior bone marrow or stem cell transplantation;
  • Currently receiving treatment with luspatercept; the last dose must have been administered ≥36 weeks before randomization;
  • Currently receiving treatment with hematopoietic stimulating agents; the last dose must have been administered ≥36 weeks before randomization;
  • History of (active or treated) ≤5 years before providing , except for nonmelanomatous skin cancer in situ, cervical carcinoma in situ, or breast carcinoma in situ;
  • History of active and/or uncontrolled cardiac or pulmonary disease ≤6 months before providing informed consent;
  • Hepatobiliary disorders;
  • Estimated \<45 milliliters per minute (mL/min)/1.73 meter (m)\^2 by Chronic Kidney Disease Epidemiology Collaboration creatinine equation;
  • Nonfasting triglycerides >440 milligrams per deciliter (mg/dL) (5 millimoles per liter [mmol/L]);
  • Active infection requiring systemic antimicrobial therapy at the time of providing informed consent;
  • Positive test for virus antibody (HCVAb) with evidence of active HCV infection, or positive test for surface antigen (HBsAg);
  • Positive test for (HIV)-1 antibody (Ab) or HIV-2 Ab;
  • History of major surgery (including splenectomy) ≤6 months before providing informed consent and/or a major surgical procedure planned during the study;
  • Current enrollment or past participation (≤12 weeks before administration of the first dose of study drug or a timeframe equivalent to 5 half-lives of the study drug, whichever is longer) in any other clinical study involving an investigational treatment or device;
  • Receiving strong /5 inhibitors that have not been stopped for ≥5 days or a timeframe equivalent to 5 half-lives (whichever is longer); or strong CYP3A4 inducers that have not been stopped for ≥4 weeks or a timeframe equivalent to 5 half-lives (whichever is longer), before randomization;
  • Receiving anabolic steroids that have not been stopped for at least 4 weeks before randomization. Testosterone replacement therapy to treat hypogonadism is allowed. The testosterone dose and preparation must be stable for ≥12 weeks before randomization;
  • Known allergy, or other , to mitapivat or its (microcrystalline cellulose, croscarmellose sodium, sodium stearyl fumarate, mannitol, and magnesium stearate, Opadry® II Blue [hypromellose, titanium dioxide, lactose monohydrate, triacetin, and Federal Food, Drug, and Cosmetic (FD\&C) Blue #2]);
  • Any medical, hematological, psychological, or behavioral condition(s) or prior or current therapy that, in the opinion of the Investigator, may confer an unacceptable risk to participating in the study and/or could confound the interpretation of the study data. Also excluded are:

    • Participants who are institutionalized by regulatory or court order
    • Participants with any condition(s) that could create undue influence (including but not limited to incarceration, involuntary psychiatric confinement, and financial or familial affiliation with the Investigator or Sponsor).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
258 participants (actual)

Study arms

  • Experimental
    Mitapivat

    Participants randomized to receive mitapivat 100 milligrams (mg), orally, twice daily (BID) for 48 weeks in the double-blind (DB) period and for up to 5 years in the open label extension (OLE) period.

    Drug: Mitapivat

  • Placebo comparator
    Placebo

    Participants randomized to receive placebo matching mitapivat, orally, BID for 48 weeks in the DB period followed by mitapivat 100 mg, orally, BID for up to 5 years in the OLE period.

    Drug: Placebo Matching Mitapivat · Drug: Mitapivat

Interventions

  • DrugPlacebo Matching Mitapivat

    Tablets

  • Tablets

    Also known as: AG-348, AG-348 sulfate hydrate, Mitapivat sulfate

07

What researchers measure

Primary outcomes

  1. Double-blind Period: Percentage of Participants Who Achieved Transfusion Reduction Response (TRR)

    TRR is defined as ≥50% reduction in transfused red blood cells (RBC) units with a reduction of ≥2 units of transfused RBCs in any consecutive 12-week period through Week 48 compared with baseline transfusion burden standardized to 12 weeks. Baseline transfusion burden standardized to 12 weeks= (12/24) × total number of RBC units transfused during 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 12 (Day 85) were considered nonresponders.

    Time frame: Double-blind Period: Baseline through Week 48

Secondary outcomes

  1. Double-blind Period: Percentage of Participants Who Achieved TRR2

    TRR2, defined as a ≥50% reduction in transfused RBC units in any consecutive 24-week period through Week 48 compared with the 24-week baseline transfusion burden, is reported. Baseline transfusion burden standardized to 24 weeks is the total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 24 (Day 169) were considered nonresponders.

    Time frame: Double-blind period: Baseline through Week 48

  2. Double-blind Period: Percentage of Participants Who Achieved TRR3

    TRR3, defined as a ≥33% reduction in transfused RBC units from Week 13 through Week 48 compared with the baseline transfusion burden standardized to 36 weeks, is reported. Baseline transfusion burden standardized to 36 weeks= (36/24) × total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 48 were considered nonresponders.

    Time frame: Double-blind period: Baseline up to Week 13 through Week 48

  3. Double-blind Period: Percentage of Participants Who Achieved TRR4

    TRR4, defined as a ≥50% reduction in transfused RBC units from Week 13 through Week 48 compared with the baseline transfusion burden standardized to 36 weeks, is reported. Baseline transfusion burden standardized to 36 weeks = (36/24) × total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 48 were considered nonresponders.

    Time frame: Double-blind period: Baseline up to Week 13 through Week 48

  4. Double-blind Period: Percent Change From Baseline in Transfused RBC Units

    Transfusion burden from Week 13 through Week 48 standardized to 36 weeks is defined as number of transfused RBC units from Day 85 through Week 48 in the Double-blind Period ×36/(Number of days from Day 85 through Week 48 in the Double-blind Period/7). Baseline transfusion burden standardized to 36 weeks= (36/24)× is the total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or within 168 days before the start of study treatment for participants randomized and dosed.

    Time frame: Double-blind Period: Baseline, Week 13 through Week 48

  5. Double-blind Period: Percentage of Participants Who Achieved Transfusion-Independence

    Transfusion-independence is defined as transfusion-free for ≥8 consecutive weeks through Week 48 in the double-blind period.

    Time frame: Double-blind Period: Baseline through Week 48

  6. Double-blind Period: Change From Baseline in Iron Levels

    Iron metabolism was assessed based on Iron levels.

    Time frame: Double-blind Period: Baseline through Week 48

  7. Double-blind Period: Change From Baseline in Serum Ferritin Levels

    Iron metabolism was assessed based on serum ferritin levels.

    Time frame: Double-blind Period: Baseline through Week 48

  8. Double-blind Period: Change From Baseline in Total Iron Binding Capacity

    Iron metabolism was assessed based on total iron binding capacity.

    Time frame: Double-blind Period: Baseline through Week 48

  9. Double-blind Period: Change From Baseline in Transferrin Saturation (TSAT) Levels

    Iron metabolism was assessed based on TSAT levels. Transferrin saturation is reported by dividing value of serum iron by total iron binding capacity.

    Time frame: Double-blind Period: Baseline through Week 48

  10. Double-blind Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs and TEAEs With Severity Greater Than or Equal to Grade 3

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the study drug. A serious adverse event (SAE) is any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are AEs with an initial onset date during the on-treatment period or worsening from baseline and includes both serious \& non-serious TEAEs. Severity of AEs was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; Version 4.03): grade 1: mild; grade 2: moderate; grade 3: severe or medically significant but not immediately life-threatening; grade 4: life threatening or disabling; grade 5: death related to AE.

    Time frame: Double-blind Period: From first dose of study drug up to week 48

  11. Open-label Extension Period: Number of Participants With TEAEs, Serious TEAEs, Related TEAEs, Related TEAEs and TEAEs With Severity of Greater Than or Equal to 3

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the study drug. A serious adverse event (SAE) is any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are AEs with an initial onset date during the on-treatment period or worsening from baseline and includes both serious \& non-serious TEAEs. Severity of abnormalities was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; Version 4.03): grade 1: mild; grade 2: moderate; grade 3: severe or medically significant but not immediately life-threatening; grade 4: life threatening or disabling; grade 5: death related to AE.

    Time frame: Open-Label Extension Period: From Week 48 up to end of study (approximately 5 years)

  12. Double-blind Period: Plasma Concentrations of Mitapivat

    Time frame: Double-blind Period: Pre-dose at Week 12; pre-dose at Week 24; pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 36

  13. Double-blind Period: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of Mitapivat

    Area under the concentration-time curve from time zero to Tlast on dosing day, calculated using the linear-log trapezoidal rule.

    Time frame: Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 36

  14. Double-blind Period: Maximum Observed Plasma Concentration (Cmax) of Mitapivat

    Time frame: Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose Week 36

  15. Double-blind Period: Time to Reach of Maximum Observed Plasma Concentration (Tmax) of Mitapivat

    Time frame: Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose Week 36

  16. Double-blind Period: Time of Last Quantifiable Concentration (Tlast) of Mitapivat

    Time frame: Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose Week 36

  17. Double-blind Period: Last Quantifiable Plasma Concentration (Clast) of Mitapivat

    Clast is the last quantifiable concentration after a single dose or within the dosing interval (tau) for multiple doses.

    Time frame: Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose Week 36

  18. Double-blind Period: Blood Concentration of Adenosine Triphosphate (ATP)

    Time frame: Double-blind Period: Pre-dose at Day 1; pre-dose at Week 12; pre-dose at Week 24; pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 36

  19. Double-blind Period: Blood Concentration of 2,3 - Diphosphoglycerate (2,3-DPG)

    Time frame: Double-blind Period: Pre-dose at Day 1; pre-dose at Week 12; pre-dose at Week 24; pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 36

08

Results

Posted May 25, 2025

Participant flow

Participants took part at 81 study sites in Malaysia,Taiwan,Thailand,Bulgaria,Brazil,Lebanon,Saudi Arabia,Turkey,United Arab Emirates,Canada, the United States,Denmark,France,Germany,Greece,Italy,Netherlands,Spain and the United Kingdom.Results are reported for 48-week DB period until primary completion date.Analysis of data for OLE period is still ongoing with anticipated completion in June 2029.Results for OLE period will be reported by June 2030.

Participant flow — Overall Study
MilestoneMitapivatPlacebo
Started17187
Safety analysis set17285
Completed15583
Not completed164
Withdrew: Randomized, never treated01
Withdrew: Adverse event91
Withdrew: Withdrawal by subject71
Withdrew: Pregnancy01

Outcome measures

PrimaryDouble-blind Period: Percentage of Participants Who Achieved Transfusion Reduction Response (TRR)

TRR is defined as ≥50% reduction in transfused red blood cells (RBC) units with a reduction of ≥2 units of transfused RBCs in any consecutive 12-week period through Week 48 compared with baseline transfusion burden standardized to 12 weeks. Baseline transfusion burden standardized to 12 weeks= (12/24) × total number of RBC units transfused during 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 12 (Day 85) were considered nonresponders.

Time frame:
Double-blind Period: Baseline through Week 48
Reported as:
Number · percentage of participants
Double-blind Period: Percentage of Participants Who Achieved Transfusion Reduction Response (TRR)
percentage of participantsMitapivatPlacebo
Double-blind Period: Percentage of Participants Who Achieved Transfusion Reduction Response (TRR)30.412.6
Statistical analysis
  • Mitapivat vs Placebo · Mantel Haenszel · p = 0.0003 · Common risk difference on response rate: 17.6 · 95% CI 8.0 to 27.2
SecondaryDouble-blind Period: Percentage of Participants Who Achieved TRR2

TRR2, defined as a ≥50% reduction in transfused RBC units in any consecutive 24-week period through Week 48 compared with the 24-week baseline transfusion burden, is reported. Baseline transfusion burden standardized to 24 weeks is the total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 24 (Day 169) were considered nonresponders.

Time frame:
Double-blind period: Baseline through Week 48
Reported as:
Number · percentage of participants
Double-blind Period: Percentage of Participants Who Achieved TRR2
percentage of participantsMitapivatPlacebo
Double-blind Period: Percentage of Participants Who Achieved TRR213.52.3
Statistical analysis
  • Mitapivat vs Placebo · Mantel Haenszel · p = 0.0003 · Common risk difference on response rate: 11.1 · 95% CI 5.1 to 17.0
SecondaryDouble-blind Period: Percentage of Participants Who Achieved TRR3

TRR3, defined as a ≥33% reduction in transfused RBC units from Week 13 through Week 48 compared with the baseline transfusion burden standardized to 36 weeks, is reported. Baseline transfusion burden standardized to 36 weeks= (36/24) × total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 48 were considered nonresponders.

Time frame:
Double-blind period: Baseline up to Week 13 through Week 48
Reported as:
Number · percentage of participants
Double-blind Period: Percentage of Participants Who Achieved TRR3
percentage of participantsMitapivatPlacebo
Double-blind Period: Percentage of Participants Who Achieved TRR314.61.1
Statistical analysis
  • Mitapivat vs Placebo · Mantel Haenszel · p = <0.0001 · Common risk difference on response rate: 13.4 · 95% CI 7.7 to 19.1
SecondaryDouble-blind Period: Percentage of Participants Who Achieved TRR4

TRR4, defined as a ≥50% reduction in transfused RBC units from Week 13 through Week 48 compared with the baseline transfusion burden standardized to 36 weeks, is reported. Baseline transfusion burden standardized to 36 weeks = (36/24) × total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 48 were considered nonresponders.

Time frame:
Double-blind period: Baseline up to Week 13 through Week 48
Reported as:
Number · percentage of participants
Double-blind Period: Percentage of Participants Who Achieved TRR4
percentage of participantsMitapivatPlacebo
Double-blind Period: Percentage of Participants Who Achieved TRR47.61.1
Statistical analysis
  • Mitapivat vs Placebo · Mantel Haenszel · p = 0.0056 · Common risk difference on response rate: 6.4 · 95% CI 1.9 to 10.9
SecondaryDouble-blind Period: Percent Change From Baseline in Transfused RBC Units

Transfusion burden from Week 13 through Week 48 standardized to 36 weeks is defined as number of transfused RBC units from Day 85 through Week 48 in the Double-blind Period ×36/(Number of days from Day 85 through Week 48 in the Double-blind Period/7). Baseline transfusion burden standardized to 36 weeks= (36/24)× is the total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or within 168 days before the start of study treatment for participants randomized and dosed.

Time frame:
Double-blind Period: Baseline, Week 13 through Week 48
Reported as:
Least squares mean · percent change
Double-blind Period: Percent Change From Baseline in Transfused RBC Units
percent changeMitapivatPlacebo
Double-blind Period: Percent Change From Baseline in Transfused RBC Units10.96 ± 2.1493.32 ± 2.846
SecondaryDouble-blind Period: Percentage of Participants Who Achieved Transfusion-Independence

Transfusion-independence is defined as transfusion-free for ≥8 consecutive weeks through Week 48 in the double-blind period.

Time frame:
Double-blind Period: Baseline through Week 48
Reported as:
Number · percentage of participants
Double-blind Period: Percentage of Participants Who Achieved Transfusion-Independence
percentage of participantsMitapivatPlacebo
Double-blind Period: Percentage of Participants Who Achieved Transfusion-Independence9.91.1
SecondaryDouble-blind Period: Change From Baseline in Iron Levels

Iron metabolism was assessed based on Iron levels.

Time frame:
Double-blind Period: Baseline through Week 48
Reported as:
Least squares mean · micromoles per liter (µmol/L)
Double-blind Period: Change From Baseline in Iron Levels
micromoles per liter (µmol/L)MitapivatPlacebo
Double-blind Period: Change From Baseline in Iron Levels-4.57 ± 0.9492.06 ± 1.280
SecondaryDouble-blind Period: Change From Baseline in Serum Ferritin Levels

Iron metabolism was assessed based on serum ferritin levels.

Time frame:
Double-blind Period: Baseline through Week 48
Reported as:
Least squares mean · micrograms per liter (µg/L)
Double-blind Period: Change From Baseline in Serum Ferritin Levels
micrograms per liter (µg/L)MitapivatPlacebo
Double-blind Period: Change From Baseline in Serum Ferritin Levels45.3 ± 88.9076.3 ± 119.84
SecondaryDouble-blind Period: Change From Baseline in Total Iron Binding Capacity

Iron metabolism was assessed based on total iron binding capacity.

Time frame:
Double-blind Period: Baseline through Week 48
Reported as:
Least squares mean · µmol/L
Double-blind Period: Change From Baseline in Total Iron Binding Capacity
µmol/LMitapivatPlacebo
Double-blind Period: Change From Baseline in Total Iron Binding Capacity-21.80 ± 3.597-1.23 ± 5.053
SecondaryDouble-blind Period: Change From Baseline in Transferrin Saturation (TSAT) Levels

Iron metabolism was assessed based on TSAT levels. Transferrin saturation is reported by dividing value of serum iron by total iron binding capacity.

Time frame:
Double-blind Period: Baseline through Week 48
Reported as:
Least squares mean · Ratio
Double-blind Period: Change From Baseline in Transferrin Saturation (TSAT) Levels
RatioMitapivatPlacebo
Double-blind Period: Change From Baseline in Transferrin Saturation (TSAT) Levels0.079 ± 0.0261-0.013 ± 0.0371
SecondaryDouble-blind Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs and TEAEs With Severity Greater Than or Equal to Grade 3

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the study drug. A serious adverse event (SAE) is any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are AEs with an initial onset date during the on-treatment period or worsening from baseline and includes both serious \& non-serious TEAEs. Severity of AEs was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; Version 4.03): grade 1: mild; grade 2: moderate; grade 3: severe or medically significant but not immediately life-threatening; grade 4: life threatening or disabling; grade 5: death related to AE.

Time frame:
Double-blind Period: From first dose of study drug up to week 48
Reported as:
Count of participants · Participants
Double-blind Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs and TEAEs With Severity Greater Than or Equal to Grade 3
ParticipantsMitapivatPlacebo
Participants with TEAEs15571
Participants with serious TEAEs1913
Participants with TEAEs related to study drug6516
Participants with any TEAE of Grade ≥ 33212
SecondaryOpen-label Extension Period: Number of Participants With TEAEs, Serious TEAEs, Related TEAEs, Related TEAEs and TEAEs With Severity of Greater Than or Equal to 3

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the study drug. A serious adverse event (SAE) is any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are AEs with an initial onset date during the on-treatment period or worsening from baseline and includes both serious \& non-serious TEAEs. Severity of abnormalities was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; Version 4.03): grade 1: mild; grade 2: moderate; grade 3: severe or medically significant but not immediately life-threatening; grade 4: life threatening or disabling; grade 5: death related to AE.

Time frame:
Open-Label Extension Period: From Week 48 up to end of study (approximately 5 years)

Results for this outcome have not been posted.

SecondaryDouble-blind Period: Plasma Concentrations of Mitapivat
Time frame:
Double-blind Period: Pre-dose at Week 12; pre-dose at Week 24; pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 36
Reported as:
Mean · nanograms per milliliter (ng/mL)
Double-blind Period: Plasma Concentrations of Mitapivat
nanograms per milliliter (ng/mL)Mitapivat
Pre-dose at Week 12122.90 ± 252.666
Pre-dose at Week 2496.55 ± 184.835
Pre-dose at Week 36129.31 ± 260.610
0.5 Hour Post-dose at Week 361282.21 ± 1007.068
1 Hour Post-dose at Week 361468.69 ± 713.248
3 Hours Post-dose at Week 36765.32 ± 372.719
5 Hours Post-dose at Week 36371.11 ± 232.556
7 Hours Post-dose at Week 36221.78 ± 172.845
SecondaryDouble-blind Period: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of Mitapivat

Area under the concentration-time curve from time zero to Tlast on dosing day, calculated using the linear-log trapezoidal rule.

Time frame:
Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 36
Reported as:
Geometric mean · hours*nanograms per milliliter (h*ng/mL)
Double-blind Period: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of Mitapivat
hours*nanograms per milliliter (h*ng/mL)Mitapivat
Double-blind Period: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of Mitapivat4365.84 ± 35.9
SecondaryDouble-blind Period: Maximum Observed Plasma Concentration (Cmax) of Mitapivat
Time frame:
Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose Week 36
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Double-blind Period: Maximum Observed Plasma Concentration (Cmax) of Mitapivat
nanograms per milliliter (ng/mL)Mitapivat
Double-blind Period: Maximum Observed Plasma Concentration (Cmax) of Mitapivat1603.00 ± 45.6
SecondaryDouble-blind Period: Time to Reach of Maximum Observed Plasma Concentration (Tmax) of Mitapivat
Time frame:
Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose Week 36
Reported as:
Median · Hours
Double-blind Period: Time to Reach of Maximum Observed Plasma Concentration (Tmax) of Mitapivat
HoursMitapivat
Double-blind Period: Time to Reach of Maximum Observed Plasma Concentration (Tmax) of Mitapivat1.000 (0.42 to 5.00)
SecondaryDouble-blind Period: Time of Last Quantifiable Concentration (Tlast) of Mitapivat
Time frame:
Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose Week 36
Reported as:
Median · Hours
Double-blind Period: Time of Last Quantifiable Concentration (Tlast) of Mitapivat
HoursMitapivat
Double-blind Period: Time of Last Quantifiable Concentration (Tlast) of Mitapivat6.750 (4.83 to 7.17)
SecondaryDouble-blind Period: Last Quantifiable Plasma Concentration (Clast) of Mitapivat

Clast is the last quantifiable concentration after a single dose or within the dosing interval (tau) for multiple doses.

Time frame:
Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose Week 36
Reported as:
Geometric mean · ng/mL
Double-blind Period: Last Quantifiable Plasma Concentration (Clast) of Mitapivat
ng/mLMitapivat
Double-blind Period: Last Quantifiable Plasma Concentration (Clast) of Mitapivat175.76 ± 85.1
SecondaryDouble-blind Period: Blood Concentration of Adenosine Triphosphate (ATP)
Time frame:
Double-blind Period: Pre-dose at Day 1; pre-dose at Week 12; pre-dose at Week 24; pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 36
Reported as:
Mean · µg/mL
Double-blind Period: Blood Concentration of Adenosine Triphosphate (ATP)
µg/mLMitapivatPlacebo
Pre-dose at Day 1224.33 ± 40.031236.23 ± 47.368
Pre-dose at Week 12283.39 ± 59.217204.19 ± 33.207
Pre-dose at Week 24279.16 ± 53.652200.84 ± 30.333
Pre-dose at Week 36280.72 ± 61.834210.47 ± 43.330
0.5 Hour Post-dose at Week 36274.75 ± 63.513206.83 ± 39.389
1 Hour Post-dose at Week 36277.45 ± 58.668209.92 ± 38.597
3 Hours Post-dose at Week 36281.70 ± 61.262213.63 ± 43.949
5 Hours Post-dose at Week 36283.76 ± 61.216208.18 ± 40.965
7 Hours Post-dose at Week 36281.47 ± 57.163212.02 ± 45.767
SecondaryDouble-blind Period: Blood Concentration of 2,3 - Diphosphoglycerate (2,3-DPG)
Time frame:
Double-blind Period: Pre-dose at Day 1; pre-dose at Week 12; pre-dose at Week 24; pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 36
Reported as:
Mean · µg/mL
Double-blind Period: Blood Concentration of 2,3 - Diphosphoglycerate (2,3-DPG)
µg/mLMitapivatPlacebo
Pre-dose at Day 1426.67 ± 75.055417.13 ± 87.448
Pre-dose at Week 12274.25 ± 76.114365.88 ± 67.238
Pre-dose at Week 24275.60 ± 78.307355.57 ± 59.420
Pre-dose at Week 36289.11 ± 78.658368.81 ± 71.481
0.5 Hour Post-dose at Week 36286.06 ± 73.409367.74 ± 62.673
1 Hour Post-dose at Week 36281.73 ± 80.276368.67 ± 66.037
3 Hours Post-dose at Week 36280.93 ± 76.916383.00 ± 91.727
5 Hours Post-dose at Week 36272.73 ± 65.327359.09 ± 72.144
7 Hours Post-dose at Week 36268.17 ± 65.942369.19 ± 75.546

Adverse events

Collected over Double-blind period: From first dose of study drug up to week 48. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mitapivat0/171 (0%)19/172 (11%)122/172 (70.9%)
Placebo0/87 (0%)13/85 (15.3%)50/85 (58.8%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventMitapivatPlacebo
PneumoniaInfections and infestations1/1722/85
Viral infectionInfections and infestations0/1721/85
Splenic haematomaBlood and lymphatic system disorders0/1721/85
CholecystitisHepatobiliary disorders1/1721/85
Cholecystitis acuteHepatobiliary disorders1/1721/85
Cholangitis acuteHepatobiliary disorders0/1721/85
ArrhythmiaCardiac disorders0/1721/85
Left ventricular dysfunctionCardiac disorders0/1721/85
Infusion related reactionInjury, poisoning and procedural complications0/1721/85
CataractEye disorders0/1721/85
Most frequent other events
Showing 10 of 19
Most frequent other events
EventMitapivatPlacebo
HeadacheNervous system disorders46/17210/85
Upper respiratory tract infectionInfections and infestations27/17214/85
Initial insomniaPsychiatric disorders24/1724/85
DiarrhoeaGastrointestinal disorders19/1727/85
FatigueGeneral disorders18/1722/85
PyrexiaGeneral disorders17/1726/85
COVID-19Infections and infestations8/1728/85
CoughRespiratory, thoracic and mediastinal disorders15/1723/85
VomitingGastrointestinal disorders8/1727/85
InfluenzaInfections and infestations14/1724/85

Baseline characteristics

Full analysis set (FAS) included all participants who were randomized.

Age, Continuous
Age, Continuous(years)MitapivatPlaceboTotal
Mean35.8 ± 11.6134.7 ± 9.7735.5 ± 11.02
Sex: Female, Male
Sex: Female, Male(Participants)MitapivatPlaceboTotal
Female9343136
Male7844122
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MitapivatPlaceboTotal
Hispanic or Latino538
Not Hispanic or Latino15879237
Unknown or Not Reported8513
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MitapivatPlaceboTotal
White9956155
Asian562278
Black or African American112
American Indian or Alaska Native000
Native Hawaiian or Other Pacific Islander000
Multiracial202
Unknown7310
Not reported6511
09

Study locations

75 sites
10

References and documents

Publications

  • Cappellini MD, Sheth S, Taher A, Al-Samkari H, Antmen AB, Beneitez D, Cannas G, Coates T, Czapla L, Dahlin JL, Estepp JH, Feenstra E, Georgiev P, Gheuens S, Price GM, Glenthoj A, Musallam KM, Osman K, Porter JB, Shao H, Uhlig K, van Beers EJ, Viprakasit V, Kuo KHM, Kattamis A; ENERGIZE-T Investigators. Efficacy and safety of mitapivat in adults with transfusion-dependent alpha-thalassaemia or beta-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2026 Sep 12;408(10559):1010-1018. doi: 10.1016/S0140-6736(26)00874-3. PubMed 42721980 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Apr 2024, 28 months.

Results were first posted in May 2025, 1 year 1 month after primary completion.

Of 18 phase 3 interventional studies under beta-Thalassemia, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2021
First posted
Feb 25, 2021
StartActual
Nov 30, 2021
Primary completionActual
Apr 11, 2024
CompletionEst.
Jun 2029
Results first posted
May 25, 2025
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42721980 ↗
Sep 28, 2026
Show all 2 updates
  1. Oct 28, 2026
    Minor edits only
    + 1 other change: verification date
  2. Sep 28, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42721980 ↗
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT04770779
Responsible party
Sponsor
First posted
Feb 25, 2021
Start date
Nov 30, 2021
Primary completion
Apr 11, 2024
Completion
Jun 2029 (estimated)
Results posted
May 25, 2025
Last update
Oct 28, 2026

Study contacts

Medical Affairs
study chair · Agios Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mitapivat

Start the discussion